Cargando…

Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study

AIMS: To examine the safety and efficacy of vibegron, a new β3‐adrenoceptor agonist, in patients aged ≥65 years, with a focus on the effects on cardiovascular system and overactive bladder (OAB) symptoms. METHODS: A post‐hoc subgroup analysis was performed of a randomized, placebo‐controlled, double...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Masaki, Takeda, Masayuki, Gotoh, Momokazu, Yokoyama, Osamu, Kakizaki, Hidehiro, Takahashi, Satoru, Masumori, Naoya, Nagai, Shinji, Minemura, Kazuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Clinical Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362047/ https://www.ncbi.nlm.nih.gov/pubmed/34139038 http://dx.doi.org/10.1002/nau.24732

Ejemplares similares

Efficacy of novel β(3)‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2018)

Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2020)

Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density
por: Yamamoto, Shota, et al.
Publicado: (2023)

Efficacy of TAC-302 for patients with detrusor underactivity and overactive bladder: a randomized, double-blind, placebo-controlled phase 2 study
por: Yoshida, Masaki, et al.
Publicado: (2022)

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
por: Frankel, Jeffrey, et al.
Publicado: (2022)

Beta3-Adrenoceptor Agonists: Possible Role in the Treatment of Overactive Bladder
por: Igawa, Yasuhiko, et al.
Publicado: (2010)

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA
por: Chen, Jing Voon, et al.
Publicado: (2022)

Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report
por: Kato, Taiki, et al.
Publicado: (2021)

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Comparison of the Uroflowmetry Parameter Results Between Transgender Males Undergoing Gender-Affirming Hormone Therapy and Age-Matched Cisgender Females: Preliminary Data
por: Matsuo, Kazuna, et al.
Publicado: (2019)

Long‐term safety and efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study)
por: Yamaguchi, Osamu, et al.
Publicado: (2018)

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting
por: Huang, Chiung-Kun, et al.
Publicado: (2020)

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
por: Staskin, David, et al.
Publicado: (2022)

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014)

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
por: Dmochowski, Roger R., et al.
Publicado: (2023)

Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
por: Staskin, David, et al.
Publicado: (2023)

Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study
por: Kakizaki, Hidehiro, et al.
Publicado: (2020)

Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women
por: Liang, Ching-Chung, et al.
Publicado: (2023)

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
por: Frankel, Jeffrey, et al.
Publicado: (2023)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
por: Weber, Michael A., et al.
Publicado: (2021)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
por: Kennelly, Michael, et al.
Publicado: (2022)

Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature
por: Masumori, Naoya
Publicado: (2013)

A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder
por: Shin, Jung Hyun, et al.
Publicado: (2023)

On the Site and Mechanism of Action of β(3)-Adrenoceptor Agonists in the Bladder
por: Andersson, Karl Erik
Publicado: (2017)

Pharmacokinetics of Mirabegron, a β(3)-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
por: Iitsuka, Hiromi, et al.
Publicado: (2013)

A Clinician’s Perspective on the Mechanism of β(3)-Adrenoceptor Agonists in the Bladder
por: Lee, Tack
Publicado: (2017)

Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists
por: Okui, Nobuo
Publicado: (2019)

Efficacy and safety of the noradrenaline reuptake inhibitor, TAS‐303, in women with stress urinary incontinence: Results of a double‐blind, randomized, placebo‐controlled, early phase II trial
por: Takahashi, Satoru, et al.
Publicado: (2020)

Cardiovascular safety of mirabegron add‐on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study
por: Katoh, Takao, et al.
Publicado: (2020)

β(2)‐Adrenoceptor agonist activity of higenamine
por: Hudzik, Thomas J., et al.
Publicado: (2021)

The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Sagvolden, Terje
Publicado: (2006)

Comparative 3D QSAR study on β(1)-, β(2)-, and β(3)-adrenoceptor agonists
por: Senthil Kumar, P., et al.
Publicado: (2009)

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
por: Varano, Susann, et al.
Publicado: (2021)

Alpha-2 adrenoceptor agonists and sepsis: improved survival?
por: Quintin, Luc
Publicado: (2010)

Paradoxical bronchoconstriction caused by β(2)-adrenoceptor agonists
por: Ayed, Khadija, et al.
Publicado: (2020)

Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria
por: Matsumoto, Seiji, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_auijktf8cfnqmvu3hbq2tcb9rk